Within the next 5 years, the results of both the Early Versus Late Intervention Trial With Estradiol (ELITE) and Kronos Early Estrogen Prevention Study (KEEPS) trial will be available.[1,101] These trials are designed to further clarify the cardiovascular protective effects of estrogen replacement when given to women in their early menopause years compared with those that have 10 years or more of menopause. If these trials demonstrate a protective effect of estrogen against atherosclerotic plaque formation, a very compelling argument for initiating estrogen therapy in the early menopause will be difficult to counter. Estrogen is already an established medication for preventing bone loss and treating menopausal symptoms in the early menopause. It is also expected that new low-dose estrogen only and combination products with new progestins will be introduced that will increase the choices for the large numbers of women entering the menopause. It is anticipated that within the next decade, healthcare providers and the general public will have a better and a more accurate understanding of the low risks associated with hormone therapy and that the accepted benefits associated with the initiation of hormone therapy for postmenopausal women within 10 years of their menopause will include protection from cardiovascular disease, prevention of bone loss, and effective treatment of menopausal symptoms.
Financial & competing interests disclosure
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Women's Health. 2011;7(4):475-485. © 2011 Future Medicine Ltd.
Cite this: Individualizing Hormone Therapy to Minimize Risk - Medscape - Jul 01, 2011.